FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to pharmaceutical composition for treatment of hyperphosphatemia, which includes iron oxyhydroxide in quantity from 10 to 80% by weight, with respect to total weight of composition, which is present in quantity over 300 mg per medical form. Composition is produced in form of medical forms, adapted for decay in oral cavity or in small quantity of liquid before swallowing. Invention also relates to method of production of pills, which contain claimed pharmaceutical composition, by direct pressing or dry granulation, as well as to pill for treatment of hyperphosphatemia, which is obtained by claimed method.
EFFECT: invention relates to application of pharmaceutical composition for production of medicine for treatment of hyperphosphatemia and patients with chronic renal insufficiency.
33 cl, 10 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION COMPRISING IRON OXY-HYDROXIDE, METHOD OF PRODUCTION THEREOF AND USE | 2013 |
|
RU2648760C2 |
| PHOSPHATE ADSORBENT BASED ON IRON (III) COMPOUNDS AND CARBOHYDRATES | 2007 |
|
RU2447933C2 |
| PHOSPHATE ADSORBENT | 2010 |
|
RU2527682C2 |
| PHARMACEUTICAL COPMOSITIONS DISSOLVING IN ORAL CAVITY | 2005 |
|
RU2405541C2 |
| ORALLY SOLUBLE AND/OR EFFERVESCENT COMPOSITIONS, CONTAINING AT LEAST ONE S-ADENOSYLMETHYONINE (SAM) | 2010 |
|
RU2524645C2 |
| SOLID MEDICINAL FORM FOR ORAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE SUBSTANCES SHOWING UNFAVORABLE ORGANOLEPTIC PROPERTIES | 1991 |
|
RU2085190C1 |
| RASAGILINE COMPOSITIONS DEGRADING IN MOUTH CAVITY | 2005 |
|
RU2389482C2 |
| CORTICOSTEROID-CONTAINING ORALLY DISINTEGRATING TABLET COMPOSITIONS FOR TREATING EOSINOPHILIC ESOPHAGITIS | 2014 |
|
RU2678695C2 |
| ORALLY DISINTEGRATING TABLET TEMAZEPAM COMPOSITIONS | 2008 |
|
RU2524638C2 |
| SOLID RAPIDLY DECOMPOSING CARBONATED COMPOSITION OF CETIRIZINE FOR ORAL ADMINISTRATION | 1999 |
|
RU2216318C2 |
